Hostname: page-component-5d84bcc8dc-zczlx Total loading time: 0 Render date: 2026-09-09T12:07:20.075Z Has data issue: false hasContentIssue false

A Trade Secret Model for Genomic Biobanking

Published online by Cambridge University Press:  01 January 2021

Extract

The current ethical norms of genomic biobankingcreating and maintaining large repositories of human DNA and/or associated data for biomedical researchhave generated criticism from every angle, at both the practical and theoretical levels. The traditional research model has involved investigators seeking biospecimens for specific purposes that they can describe and disclose to prospective subjects, from whom they can then seek informed consent. In the case of many biobanks, however, the institution that collects and maintains the biospecimens may not itself be directly involved in research, instead banking the biospecimens and associated data for other researchers. Moreover, the future uses of biospecimens may be unknown, if not unknowable, at the time of collection. Biobanking may thus stretch the meanings of inform and consent to their breaking point: if you cannot inform subjects about what their biospecimens will be used for (because you do not know), what can they consent to? Given that informed consent by individual subjects is the ethical gold standard, the seeming dilution of the concept in the context of biobanking is a profound problem.

Information

Type
Independent
Copyright
Copyright © American Society of Law, Medicine and Ethics 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable